Ceftriaxone-AKOS - description of the drug, instructions for use, reviews

Write a review

Reviews: 0

Manufacturers: Synthesis

Active ingredients

• Ceftriaxone

Disease class

• Bacterial meningitis, not elsewhere classified
• Pneumococcal meningitis
• Otitis media in viral diseases classified elsewhere
• Acute and subacute endocarditis
• Acute sinusitis
• Acute upper respiratory tract infection of multiple and unspecified localization
• Pneumonia caused by Haemophilus influenzae [Afanasyev-Pfeffer bacillus]
• Pneumonia caused by Klebsiella pneumoniae
• Pneumonia caused by Escherichia coli
• Pneumonia without specifying the pathogen
• Acute lower respiratory tract respiratory infection, unspecified
• Peritonsillar abscess
• Bronchitis, not specified as acute or chronic
• Bronchiectasis
• Abscess of the lung and mediastinum
• Pyothorax
• Disease of the stomach and duodenum, unspecified
• Peritonitis
• Lesions of the peritoneum in infectious diseases classified elsewhere
• Local infection of skin and subcutaneous tissue, unspecified
• Bile duct stones with cholangitis
• Acute cholecystitis
• Cholangitis
• Lesions of the gallbladder, biliary tract and pancreas in diseases classified elsewhere
• Infectious myositis
• Synovitis and tenosynovitis
• Tendon sheath abscess
• Abscess of the bursa
• Other infectious bursitis
• Osteomyelitis
• Acute tubulointerstitial nephritis
• Pleurisy
• Other salmonella infections
• Shigelosis
• Bacterial intestinal infection, unspecified
• Diarrhea and gastroenteritis of suspected infectious origin
• Meningococcal infection
• Streptococcal septicemia
• Septicemia, unspecified
• Syphilis, unspecified
• Gonococcal infection
• Chancroid (soft chancroid)
• Lyme disease
• Other and unspecified infectious diseases
• Infection associated with a procedure, not elsewhere classified
• Post-traumatic wound infection, not elsewhere classified
• Thermal and chemical burns of unspecified localization
• Surgical practice
• Chronic tubulointerstitial nephritis
• Urinary tract infection without established localization
• Inflammatory diseases of the male genital organs, not elsewhere classified
• Inflammatory diseases of the breast
• Inflammatory disease of the uterus, other than the cervix
• Inflammatory disease of the cervix
• Parametritis and pelvic cellulitis, unspecified
• Inflammatory diseases of the female pelvic organs, unspecified
• Inflammatory diseases of the female pelvic organs caused by syphilis (A51.4, A52.7)
• Gonococcal inflammatory diseases of the female pelvic organs

Clinical and pharmacological group

• Not indicated. See instructions

Pharmacological action

• Antibacterial

Pharmacological group

• Cephalosporins

Composition and release form

in a blister pack 10 pcs.; in a cardboard pack of 5 packs or in jars of 20 pcs.; in a cardboard pack 1 jar.

in aluminum tubes of 30 g; in a cardboard pack 1 tube.

Overdose

The drug must be taken in strict accordance with the dosage prescribed in the medical institution. If you increase the prescribed dose yourself, this may cause an overdose. At the same time, a strong decrease in blood pressure is often accompanied by pulmonary embolism, myocardial infarction, and impaired blood flow in the brain.

Taking too much of the drug may cause an overdose

The condition requires immediate medical attention using symptomatic therapy and hemodialysis. Lack of timely assistance leads to the development of severe complications and death of the patient.

Pharmacodynamics

Capsules. Affects metabolic processes in hyaline and fibrous cartilage, reduces degenerative changes in the cartilage tissue of joints, stimulates the biosynthesis of glycosaminoglycans. Slows down bone resorption and reduces calcium loss, accelerates bone tissue restoration processes. When treated with Chondroitin-AKOS, pain decreases and mobility of the affected joints improves. The therapeutic effect persists for a long time after the end of the course of treatment.

Ointment. Chondroitin-AKOS contains chondroitin sulfate, a stimulator for the restoration of cartilage tissue in joints (chondroprotector), obtained from bovine tracheal cartilage, and dimethyl sulfoxide.

Chondroitin sulfate is a high-molecular mucopolysaccharide that inhibits the processes of destruction of cartilage tissue and accelerates the processes of its restoration. Suppresses enzymes that cause damage to cartilage tissue and prevents its degradation; stimulates the biosynthesis of glycosaminoglycans by chondrocytes; promotes the restoration of the joint capsule and cartilaginous surfaces of the joints, increases the production of intra-articular fluid. Improves phosphorus-calcium metabolism and reduces calcium loss in cartilage tissue, slows down bone resorption, normalizes metabolism in hyaline tissue, accelerates regeneration (recovery) processes and inhibits degeneration (destruction) of cartilage tissue. Structurally close to heparin, it prevents the formation of fibrin blood clots in the synovial and subchondral microvasculature. As a result of the effect, pain decreases and mobility of the affected joints increases.

Dimethyl sulfoxide, which is part of the ointment, has an anti-inflammatory, analgesic and fibrinolytic effect, promotes better penetration of chondroitin sulfate through cell membranes deep into tissues.

Chondroitin-AKOS ointment has an analgesic and anti-inflammatory effect, normalizes metabolism and stimulates restoration processes in joint tissues, leads to a reduction or disappearance of pain in the joints, improves joint mobility, and slows down the progression of osteoarthrosis and osteochondrosis.

Possible side effects

The abstract for Captopril indicates the possibility of developing the following negative consequences:

• numbness, tingling in the limbs;
• frequent headaches turning into migraines;
• fog, dizziness;
• chronic fatigue, muscle weakness;
• increased heart rate;
• disruption of the functioning of the digestive system (diarrhea or constipation, nausea, belching, heartburn, change in taste, loss of appetite, increased concentration of bilirubin, hepatitis, cholecystitis);
• changes in blood composition of a qualitative and quantitative nature;
• dysfunction of the urinary system.

Severe side effects include bronchospasms, Quincke's edema, swollen lymph nodes, and serum sickness.

Incorrect use of the medicine leads to side effects

Important! If such reactions occur, you should stop therapy and seek medical help.

Contraindications

For both dosage forms: hypersensitivity to the components of the drug.

For capsules additionally: children under 15 years of age (due to lack of accurate data).

With caution: bleeding and tendency to bleeding, thrombophlebitis.

For ointment additionally: acute inflammatory processes in the wound area; widespread tissue necrosis; excessive granulation; violation of the integrity of the skin at the sites of intended application.

With caution: do not use Chondroitin-AKOS ointment without consulting a doctor during pregnancy and breastfeeding, as well as in childhood.

Who is the drug prescribed to?

Indications for the use of Captopril Akos are quite limited. The drug is prescribed for the following conditions:

• hypertension due to impaired renal function;
• increased blood pressure, the etiology of which cannot be determined;
• hypertension of a malignant nature, when blood pressure cannot be normalized with medications;
• in complex therapy of left ventricular dysfunction, to prevent heart attack and other complications.

The drug is indicated for patients with arterial hypertension

The medicine is used both as an independent treatment and as an adjuvant therapy for conditions in patients characterized by increased blood pressure.

Directions for use and doses

Orally, during or after meals, with at least 1/2 glass of water.

Adults and adolescents over 15 years of age are prescribed 1 g/day (2 capsules 2 times a day).

The recommended duration of the initial course of treatment is 6 months, the period of action of the drug after its discontinuation is 3–5 months, depending on the location and stage of the disease, the duration of repeated courses of treatment is determined by the doctor.

Externally. Chondroitin-AKOS ointment is applied 2-3 times a day to the skin over the lesion and rubbed in for 2-3 minutes until completely absorbed. Typically, the course of treatment ranges from 2–3 weeks to 2 months. If necessary, the course of treatment is repeated.

Effect of the drug

Captopril Akos helps to reduce the rate of conversion of the hormone angiotensin I to angiotensin II, which ensures a decrease in blood pressure and the production of aldosterone by the adrenal cortex.

In this case, there is a decrease in the measure of tension in the wall of the left ventricle of the heart at the end of diastole, as well as the tension in the wall of the left ventricle during systole (pre- and afterload). The medicine reduces peripheral arterial resistance. In addition, the tablets lead to a decrease in the degradation of bradykinin and an increase in the formation of prostaglandin.

Plasma renin does not affect the effect of the drug. Normalization of blood pressure occurs even at medium and low concentrations of this substance.

Long-term therapy with the described drug can reduce myocardial hypertrophy and increase the heart's tolerance to physical activity.

Blood pressure decreases after taking the medication

The largest amount of the active component in the body is observed after 1–1.5 hours. The main actions of the product include:

• restoration of blood circulation in blood vessels;
• decreased bradykinin suppression;
• normalization of renal and coronary blood flow;
• drop in aldosterone production in the blood.

Important! To ensure the best results, it is recommended to take Captopril Akos only as prescribed by a doctor, strictly following the dosage and dosage regimen.

Patient reviews

Stepan, Samara “My sister is not yet 30, but she already suffers from periodic increases in blood pressure. She has a severe headache, tinnitus, and fatigue. I advised her on Captopril Akos, since I myself have been using this medicine for a long time, and it helps me well. The drug also worked for my sister, now the pills are always in her medicine cabinet, they have become a real first aid.”

Irina, Tomsk “Several years ago I was diagnosed with stage 2 hypertension, since then I have always had antihypertensive drugs at hand. I don’t use Captopril Akos every day; the doctor prescribed a milder medicine, but in case of a sharp and severe increase in blood pressure, this drug is simply necessary. I put the tablet under my tongue and after 20-30 minutes the condition improves. I think this remedy is an excellent way to prevent complications.”

Maxim, Kirov “Captopril Akos is really good at lowering blood pressure, but you need to know that you should not take more than 3 tablets per day, this can cause very serious consequences. One day my blood pressure increased significantly and I had to call an ambulance. It was Captopril Akos that knocked him down, and since then I always have this remedy with me.”

Stanislav, Moscow “I rarely use medications on my own, but recently I had to do it. While relaxing in nature, I suddenly felt sick, dizzy, had tinnitus, and increased blood pressure. My friends had Captopril tablets with them. Fortunately, they suited me well and my blood pressure dropped quickly, without any negative consequences for me. After that, I discussed the case with my doctor, and he advised me to keep the funds with me at all times.”

Ibuprofen-akos suspension 100mg/5ml orange 100 ml

With simultaneous use, ibuprofen reduces the effect of antihypertensive drugs (ACE inhibitors, beta-blockers), diuretics (furosemide, hydrochlorothiazide).

When used simultaneously with anticoagulants, their effect may be enhanced.

When used simultaneously with GCS, the risk of side effects from the gastrointestinal tract increases.

When used simultaneously, ibuprofen can displace indirect anticoagulants (acenocoumarol), hydantoin derivatives (phenytoin), and oral hypoglycemic drugs, sulfonylurea derivatives, from compounds with blood plasma proteins.

When used simultaneously with amlodipine, a slight decrease in the antihypertensive effect of amlodipine with acetylsalicylic acid is possible - the concentration of ibuprofen in the blood plasma with baclofen decreases - a case of increased toxic effect of baclofen is described.

When used simultaneously with warfarin, an increase in bleeding time is possible; microhematuria and hematomas with captopril were also observed - a possible decrease in the antihypertensive effect of captopril with cholestyramine - a moderately pronounced decrease in the absorption of ibuprofen.

When used simultaneously with lithium carbonate, the concentration of lithium in the blood plasma increases.

When used simultaneously with magnesium hydroxide, the initial absorption of ibuprofen with methotrexate increases - the toxicity of methotrexate increases.

The simultaneous use of NSAIDs and cardiac glycosides can lead to worsening heart failure, a decrease in glomerular filtration rate and an increase in the concentration of cardiac glycosides in the blood plasma.

There is evidence of the likelihood of an increase in the concentration of methotrexate in the blood plasma during the use of NSAIDs.

With simultaneous use of NSAIDs and cyclosporine, the risk of nephrotoxicity increases.

NSAIDs may reduce the effectiveness of mifepristone, so taking NSAIDs should be started no earlier than 8-12 days after stopping mifepristone.

Concomitant use of NSAIDs and tacrolimus may increase the risk of nephrotoxicity.

Concomitant use of NSAIDs and zidovudine may lead to increased hematotoxicity.

There is evidence of an increased risk of hemarthrosis and hematomas in HIV-positive patients with hemophilia who received concomitant treatment with zidovudine and ibuprofen.

In patients receiving concomitant treatment with NSAIDs and quinolone antibiotics, the risk of seizures may increase.

In patients receiving concomitant NSAIDs and myelotoxic drugs, hematotoxicity increases.

With the simultaneous use of ibuprofen and cefamandole, cefoperazone, cefotetan, valproic acid, plicamycin, the incidence of hypoprothrombinemia increases.

With the simultaneous use of ibuprofen and drugs that block tubular secretion, there is a decrease in excretion and an increase in plasma concentration of ibuprofen.

With the simultaneous use of ibuprofen and inducers of microsomal oxidation (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants), there is an increase in the production of hydroxylated active metabolites and an increased risk of developing severe intoxications.

special instructions

If you miss taking a medication, the dose does not need to be increased; the next dose of medication is taken according to the prescribed regimen.

Despite the fact that the drug has positive reviews, it is highly not recommended to use it on your own.

It is prohibited to combine the product with alcoholic beverages.

During treatment, blood pressure should be measured regularly.

Patients undergoing therapy with the drug should undergo regular medical examinations and tests to monitor the vital systems of the body.